Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

Jacopo Sabbatinelli1,2, Stefania Castiglione3, Federica Macrì3, Angelica Giuliani1*, Deborah Ramini4, Maria Cristina Vinci5, Elena Tortato6, Anna Rita Bonfigli7, Fabiola Olivieri1,4 and Angela Raucci3

Abstract

Background: Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retrospective cohort study, we explored the association of circulating levels of soluble RAGE (sRAGE) isoforms, i.e., endogenous secretory esRAGE and cleaved cRAGE, AGEs and their respective ratios with 15-year all-cause mortality in type 2 diabetes.

Methods: Baseline AGEs and sRAGE isoforms concentration were measured by ELISA in 362 patients with type 2 diabetes and in 125 age- and gender-matched healthy control subjects (CTR). Independent predictors of mortality were determined using Cox proportional-hazards models and used to build and validate a nomogram for all-cause mortality prediction in type 2 diabetes.

Results: AGEs, total sRAGE, cRAGE and the AGEs/sRAGE and AGEs/esRAGE ratios were significantly increased in patients with type 2 diabetes compared to CTR (p < 0.001). In CTR subjects, but not in type 2 diabetes patients, a significant negative correlation between cRAGE and age was confirmed (p = 0.003), whereas the AGEs/sRAGE (p = 0.032) and AGEs/cRAGE (p = 0.006) ratios were positively associated with age. At an average follow-up of 15 years (4,982 person-years), 130 deaths were observed. The increase in the AGEs/cRAGE ratio was accompanied by a higher risk of all-cause mortality in patients with type 2 diabetes (HR per each SD increment = 1.30, 95% CI 1.15–1.47; p < 0.001).

Moreover, sRAGE was associated with the development of major adverse cardiovascular events (MACE) in type 2 diabetes patients without previous MACE (OR for each SD increase: 1.48, 95% CI 1.11–1.89). A nomogram based on age, sex, HbA1c, systolic blood pressure, and the AGEs/cRAGE ratio was built to predict 5-, 10- and 15-year survival in
Advanced glycation end products (AGEs) and the receptor for advanced glycation end products (RAGE) activate cell signaling pathways modulating inflammatory gene expression profile in several chronic inflammatory disorders [1–3]. AGEs are the products of non-enzymatic glycation and oxidation of proteins and lipids and under physiological conditions, anti-glycation defenses are sufficient to prevent their accumulation [2]. A significantly increased burden of AGEs was described in aging and age-related diseases (ARDs), primarily in diabetes mellitus [2, 4], and their levels, measured using skin autofluorescence, were associated with a significant increase in the incidence of major adverse cardiovascular events (MACE) in a multitude of chronic conditions, including heart failure [5], type 2 diabetes [6], and end-stage renal disease [7]. The contribution of AGEs in fostering endothelial dysfunction and exacerbating atherosclerosis has been confirmed by their robust association with non-invasive measures of arterial stiffness, which is more pronounced in men and younger individuals [8]. The membrane-bound RAGE (FL-RAGE) is a pattern recognition receptor that recognizes AGEs and several other ligands, some of which act as damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) [9–11]. Under physiological conditions, RAGE is expressed in the lungs while is almost undetectable in other tissues [12, 13]; however, its levels are induced by ligand accumulation [14–16]. The cytoplasmic domain of RAGE binds to the formin DIAPH1 that is essential for RAGE/ligand-mediated activation and production of reactive oxygen species (ROS) eventually promoting inflammatory processes in ARDs [17, 18].

The soluble forms of RAGE, collectively named (sRAGE), are also present in the blood and consist of the RAGE ectodomain, produced by proteolytic cleavage (cRAGE) of the membrane-bound form by metalloproteases or through alternative splicing as endogenous secretory RAGE (esRAGE), which is actively secreted [19]. sRAGE does not transduce signal upon ligand binding, acting as a decoy molecule to restrain the RAGE/ligand induced cell activation [20]. Accordingly, sRAGE administration reduces diabetes and atherosclerosis tissue remodeling, age-associated cardiac fibrosis and neointima expansion after vessel injury [13, 21–23].

In humans, altered circulating sRAGE and esRAGE levels have been related to disease states or their risk factors. Many studies reported lower sRAGE or esRAGE levels in subjects with cardiometabolic conditions like metabolic syndrome [24], hypertension [24, 25], obesity [26] and prediabetes [27–29]. sRAGE also decreases with aging in healthy subjects [30–32]. In contrast, sRAGE elevation has been associated with chronic diabetes [33, 34], frailty [35] and people with diminished kidney function [36].

The potential prognostic value of sRAGE as a marker of disease and the occurrence of adverse events seems to be suitable for individuals with chronic disease or multimorbidity and not for the general population [37–40]. Concerning diabetes, increased concentrations of sRAGE were associated with increased all-cause and cardiovascular (CV) mortality in type 1 diabetes [41, 42]. In patients with type 2 diabetes, higher levels of sRAGE were independently associated with new or worsening kidney disease and mortality over 5 years follow-up [43]. Prospective studies underlined significant positive association between sRAGE and esRAGE and the incident of coronary artery disease (CHD) in type 2 diabetes [38, 44].

Recently, the ratio of AGEs/sRAGE has been proposed as a more effective biomarker of organ damage than AGEs or sRAGE variants separately [31, 45, 46]. Moreover, a different predictive capability of esRAGE and cRAGE as markers of CV risk factors have been evidenced lately [29, 31, 32]. For instance, we have published that in a healthy population and long living individuals (LLIs), cRAGE negatively relates with aging while esRAGE is a more appropriate biomarker of obesity and longevity [31, 32]. Hence, new aspects should be taken in consideration in order to define the prognostic value of AGEs/sRAGE isoforms axis in human pathologies.

Herein, we simultaneously determined circulating levels of both sRAGE isoforms—esRAGE and cRAGE—AGEs and their respective ratios in patients with type 2 diabetes and in age- and gender-matched healthy control subjects and investigated their association with 15-year all-cause mortality in type 2 diabetes.
**Methods**

**Samples**

362 patients with type 2 diabetes and 125 age-and-gender matched healthy control subjects (CTRs) were randomly selected from a cohort of 562 patients with type 2 diabetes and 599 CTRs enrolled from central Italy [47]. The study was approved by the Institutional Review Board of IRCCS INRCA hospital (approval no. 34/CdB/03). Information such as vital signs, anthropometric measures, medical history, behavioral data including diet and physical activity were available for study participants. Written informed consent was obtained from each subject in accordance with principles of the Declaration of Helsinki. Type 2 diabetes was diagnosed according to the American Diabetes Association (ADA) criteria, i.e., patients having a glycated Hemoglobin A1c (HbA1C) ≥6.5% or fasting blood glucose ≥126 mg/dl or 2-hour blood glucose levels ≥200 mg/dl after the oral glucose tolerance test (OGTT), or a random blood glucose ≥200 mg/dl when severe diabetes symptoms are present [48]. Inclusion criteria for patients with diabetes were body mass index (BMI) <40 kg/m², age 40–87 years, ability, and willingness to give written informed consent. The presence/absence of diabetic complications was established as follows: diabetic retinopathy by fundoscopy through dilated pupils and/or fluorescence angiography; incipient nephropathy, defined as a urinary albumin excretion rate >30 mg/24 h and a normal creatinine clearance; neuropathy established by electromyography; ischemic heart disease defined by clinical history, and/or ischemic electrocardiographic alterations; peripheral vascular disease, including atherosclerosis obliterans and cerebrovascular disease based on history, physical examinations and Doppler velocimetry. Among the 362 patients, 73 were affected by neuropathy, 27 by peripheral artery disease, 52 by diabetic kidney disease and 95 by retinopathy. Fifty-three patients had a history of major adverse cardiovascular events (MACE).

Fasting blood samples of all subjects were processed to obtain plasma and stored at −80 °C.

**Measurement of RAGE isoforms and AGEs**

Circulating levels of sRAGE isoforms were determined by commercial ELISA kits following manufacturer’s instructions. Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [29, 31, 32].

AGEs were measured by an ELISA assay from Biolabs (STA-817 Cell Biolabs, INC. San Diego, CA) following manufacturer’s instructions. AGEs levels (µg/ml) were divided by sRAGE isoform levels (pg/ml) to obtain the ratio (µg/pg).

**Statistical analysis**

Continuous variables were reported as either mean and standard deviation or median and interquartile range (IQR) based on their distribution (assessed using Shapiro-Wilk test). For comparisons between groups, Mann-Whitney U test and Kruskal-Wallis followed by Dunn post hoc test were used. Spearman correlation was used to assess correlations between continuous variables, which were visualized by correlation plots generated by the Jamovi software, version 2.2.1. Quantile regression was used to evaluate the impact of type 2 diabetes complications and treatments on the levels of AGEs and sRAGE isoforms. The association between AGEs and sRAGE isoforms and the follow-up endpoints was investigated by Cox proportional hazards analysis (adjusted for established risk factors and potential confounders) with 95% confidence intervals. Based on the results of the multivariate Cox regression analysis, a nomogram for predicting 5-, 10- and 15-year survival in type 2 diabetes was built using the “hdnom” package (version 6.0.0) for R, version 4.1 [49]. Specifically, a penalized Cox regression model trained with an adaptive elastic net procedure using 10-fold cross-validation on the whole sample. The adaptive elastic net is an adaptation of the original Cox regression for survival analysis which can handle correlated features and performs variable selection. Nomogram performance was assessed on 100 bootstrap samples. The predictive efficacy was assessed with calibration and discrimination statistics. Reclassification was assessed by use of the continuous net reclassification improvement (NRI-€) [50].

**Results**

Baseline demographical and biochemical characteristics of 362 patients affected by type 2 diabetes mellitus (median age 63.0 yrs., IQR 56.0–73.5 yrs) and 125 age- and gender-matched healthy control subjects (CTR; median age 67.0 yrs., IQR 60.0–72.0 yrs.) are reported in Table 1. Median type 2 diabetes duration was 12.5 yrs. (IQR 6.0–24.0 yrs.). No missing data were identified. The prevalence of diabetic complications was as follows: retinopathy, 26%; nephropathy, 15%; neuropathy, 20%; peripheral artery disease, 8%; MACE, 15%. Patients with type 2 diabetes showed significantly increased weight, BMI, waist-hip ratio (WHR), systolic (SBP) and diastolic (DBP) blood pressure, triglycerides, fasting glucose and insulin, HbA1C, HOMA index, creatinine, alanine...
Table 1 Baseline demographical and biochemical characteristics of healthy control subjects (CTR) and patients with type 2 diabetes

| Variables                                 | CTR (n = 125) | Type 2 diabetes (n = 362) | P   |
|-------------------------------------------|---------------|---------------------------|-----|
| Age (years)                               | 63.0 (56.0–73.5) | 67.0 (60.0–72.0)          | 0.114|
| Gender (Males, %)                         | 59 (47%)      | 200 (55%)                 | 0.145|
| BMi (Kg/m²)                               | 26.6 (24.0–29.2) | 28.3 (25.9–31.4)          | <0.001|
| Weight (Kg)                               | 73 (65–80)    | 78 (70–87)                | <0.001|
| Waist-hip ratio                           | 0.90 (0.84–0.96) | 0.94 (0.89–0.98)          | <0.001|
| Systolic blood pressure (mmHg)            | 133 (125–139)  | 136 (129–143)             | <0.001|
| Diastolic blood pressure (mmHg)           | 85 (80–93)    | 90 (85–96)                | <0.001|
| Total cholesterol (mg/dL)                 | 217.5 (186.3–238.0) | 209 (181.8–235.0)        | 0.124|
| HDL-C (mg/dL)                             | 56.5 (47.3–67.8) | 50.0 (43.0–60.0)          | <0.001|
| Triglycerides (mg/dL)                     | 92.5 (62.3–131.0) | 115.0 (83.8–163.3)       | <0.001|
| ApoA1 (mg/dL)                             | 176.0 (155.0–203.8) | 164.5 (149.0–187.0)     | 0.001|
| ApoB (mg/dL)                              | 101.5 (83.5–121.0) | 101.0 (85.0–122.0)      | 0.822|
| Glucose (mg/dL)                           | 940.0 (890–100.0) | 152.0 (133.8–186.0)     | <0.001|
| HbA1C (%)                                 | 5.7 (5.5–6.1)  | 7.3 (6.5–8.1)             | <0.001|
| Insulin (UI/mL)                           | 4.70 (3.44–6.96) | 5.80 (3.69–8.83)         | 0.003|
| HOMA index                                | 1.12 (0.77–1.61) | 2.17 (1.42–3.61)         | <0.001|
| Creatinine (mg/dL)                        | 0.85 (0.70–1.00) | 0.90 (0.70–1.00)         | 0.043|
| eGFR (mL/min)                             | 82.5 (68.3–89.5) | 81.3 (66.1–87.5)          | 0.009|
| Azotemia (mg/dL)                          | 38.0 (33.0–44.0) | 38.0 (32.0–46.3)          | 0.706|
| Uric acid (mg/dL)                         | 4.8 (4.1–5.5)  | 4.6 (4.0–5.4)             | 0.241|
| Alanine aminotransferase (U/L)            | 36 (32–42)    | 39 (33–48)                | 0.002|
| Aspartate aminotransferase (U/L)          | 21 (17–25)    | 20 (16–25)                | 0.104|
| Gamma-glutamitransferase (U/L)           | 45 (35–56)    | 51 (41–62)                | <0.001|
| Total bilirubin (mg/dL)                   | 0.7 (0.6–0.9)  | 0.6 (0.5–0.8)             | 0.029|
| WBC (n/mm³)                               | 6.17 (5.09–7.29) | 6.56 (5.60–7.62)        | 0.003|
| Hemoglobin (g/dL)                         | 14.1 (13.4–15.0) | 14.5 (13.6–15.4)        | 0.033|
| Platelets (n/mm³)                         | 229 (195–273)  | 210 (176–251)             | 0.008|
| hs-CRP (mg/L)                             | 1.98 (0.87–5.04) | 2.73 (1.08–4.78)        | 0.017|
| PAI-1 (ng/mL)                             | 17.8 (11.9–24.7) | 18.5 (13.1–25.3)       | 0.674|
| Fibrinogen (mg/dL)                        | 296 (249–369)  | 303 (257–344)             | 0.221|
| Iron (µg/dL)                              | 79 (63–100)    | 81 (66–97)                | 0.375|
| Ferritin (ng/mL)                          | 97.8 (490–187.3) | 71.5 (39.6–150.7)       | 0.445|
| Disease duration (years)                  | –             | 12.5 (6.0–24.0)           | –|
| Relevant medications (n, %)               | –             | –                         | –|
| Any T2DM medication                       | –             | 264 (73%)                 | –|
| Metformin                                 | –             | 133 (37%)                 | –|
| Sulphonylureas                            | –             | 173 (48%)                 | –|
| Glinides                                  | –             | 7 (2%)                    | –|
| Insulin                                   | –             | 60 (17%)                  | –|
| Vitamin K antagonists                     | –             | 39 (11%)                  | –|
| Statins                                   | 4 (3%)        | 60 (17%)                  | <0.001|
| Type 2 diabetes complications (n, %)       | –             | 194 (53%)                 | –|
| Any complication                          | –             | 95 (26%)                  | –|
| Diabetic kidney disease                   | –             | 52 (15%)                  | –|
| Neuropathy                                | –             | 73 (20%)                  | –|
| Peripheral artery disease                 | –             | 27 (8%)                   | –|
| MACE                                      | –             | 53 (15%)                  | –|

Data are median (IQR) for continuous variables and n (%) for categorical variables. P value from Mann-Whitney test for continuous variables and from chi-squared tests of association for categorical variables. Significant differences are in bold.
aminotransferase, gamma-glutamyl transferase, white blood cells, hemoglobin, and high-sensitivity C-reactive protein (hs-CRP). On the contrary, total bilirubin and platelets were significant lower in type 2 diabetes compared to CTR. Moreover, serum levels of total cholesterol, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C) and apolipoprotein A1 (ApoA1) were lower in patients, due to the higher prevalence of statin therapy.

Baseline assessment of AGEs and sRAGE isoforms
The comparisons of AGEs and the different isoforms of sRAGE between type 2 diabetes and CTR groups were reported in Table 2. AGEs as well as sRAGE levels were significantly increased in type 2 diabetes compared to CTR. The increase of sRAGE in type 2 diabetes mainly depends on cRAGE changes rather than esRAGE. Furthermore, the AGEs/sRAGE and AGEs/esRAGE ratios were increased in patients with type 2 diabetes while AGEs/cRAGE remained unchanged between the two groups. No significant gender-related differences were observed in both groups (data not shown).

Table 2 Comparison of AGEs, sRAGE isoforms, and their ratios between healthy controls (CTR) and patients with type 2 diabetes

|                  | CTR (n = 125)                         | Type 2 diabetes (n = 362) | P-value |
|------------------|---------------------------------------|--------------------------|---------|
| sRAGE (pg/mL)    | 430.6 (275.0–595.9)                   | 667.7 (464.8–929.9)      | <0.001  |
| esRAGE (pg/mL)   | 242.9 (153.9–362.3)                   | 283.5 (138.0–432.9)      | 0.312   |
| cRAGE (pg/mL)    | 149.0 (44.7–267.8)                    | 324.1 (173.7–521.0)      | <0.001  |
| AGEs (µg/ml)     | 4.41 (2.45–6.23)                      | 11.15 (4.43–21.40)       | <0.001  |
| AGEs/sRAGE       | 0.009 (0.005–0.018)                   | 0.017 (0.006–0.035)      | <0.001  |
| AGEs/esRAGE      | 0.016 (0.010–0.026)                   | 0.055 (0.024–0.099)      | <0.001  |
| AGEs/cRAGE       | 0.030 (0.011–0.103)                   | 0.036 (0.011–0.095)      | 0.914   |

Data are median (IQR), P-values for Mann–Whitney U test. Significant differences are in bold.

The levels of AGEs and sRAGE variants were analyzed according to the presence of the micro- and macrovascular complications of diabetes, i.e., neuropathy, nephropathy, retinopathy, peripheral vascular disease, and MACE (Table 4). Results of the quantile regression model, adjusted for age and HbA1c, revealed that nephropathy was associated with decreased sRAGE levels and increased AGEs/sRAGE and AGEs/esRAGE ratios. Retinopathy was associated with increased cRAGE and reduced AGEs levels, AGEs/sRAGE and AGEs/cRAGE ratios. The presence of atherosclerotic vascular disease was associated with increased cRAGE levels, while subjects with history of MACE showed a reduced AGEs/esRAGE ratio. Moreover, patients under insulin therapy were characterized by significantly reduced AGEs/sRAGE, AGEs/cRAGE and AGEs levels, after adjustment for age and HbA1c (Table 5).

Prognostic value of sRAGE isoforms in the follow-up of type 2 diabetes
After 15 years of follow-up (4,982 person-years), 130 out of 352 patients with type 2 diabetes were deceased (36.9%). The observed crude mortality was 26.1 per 1000
person-years. Mean survival was longer in patients without complications compared to patients with at least one complication (181.0 [173.9–188.1] vs. 160.8 [152.8–168.9] months, p < 0.001).

Cox regression models were applied to identify association between AGEs and sRAGE isoform levels and all-cause mortality in type 2 diabetes. Table 6 shows the univariate HRs for the established all-cause mortality risk predictors—age, sex, BMI, disease duration, SBP, HbA1c, blood lipids, eGFR, hs-CRP, and ongoing treatments—and for AGEs, sRAGE isoforms, and their ratios. Cox regression univariate and multivariate analyses, adjusted for the abovementioned confounders, revealed an increased mortality risk for patients with increased AGEs/cRAGE ratio (Table 6). The combined model, which includes the established risk factors and the ratios between AGEs and sRAGE isoforms as predictors, confirmed that each SD increase in the AGEs/cRAGE ratio is accompanied by a higher risk of mortality in type 2 diabetes (HR: 1.30, 95% CI 1.15–1.47; Table 6).

Based on the results of the Cox regression models, an adaptive elastic net regression model and multivariate Cox regression analysis was computed to predict survival at 5, 10 and 15 years in type 2 diabetes based on the following variables: age, disease duration, sex, HbA1c, SBP, hs-CRP, and the AGEs/cRAGE ratio. Disease duration and hs-CRP were excluded from the model by the elastic-net regression process. Figure 4A presents the model in the form of a nomogram that provides the long-term survival probabilities corresponding to a particular total score. The total score for a patient is obtained by adding up the scores for each of the six predictors. Internal validation with bootstrap resampling performed on the whole sample showed that the AUCs for the all-cause mortality prediction nomogram were 0.688, 0.779 and 0.764 at 5, 10 and 15 years respectively (Fig. 4B). The internal calibration plot revealed a good agreement between the observed and predicted values (calibration slope 1.32, y-intercept = −0.22 [95% CI −0.76 to 0.33]; Fig. 4C). Based on the risk profile predicted by
the nomogram, 4 homogeneous groups of patients were generated, and Kaplan-Meier survival curves were constructed (Fig. 4D). The log-rank test confirmed that the survival curves of patients grouped according to the nomogram-based mortality risk score were significantly different ($p = 6.5 \times 10^{-13}$).

AGEs and the sRAGE isoforms were also evaluated as predictors of the development of diabetic complications. While none of the parameters was significantly associated with development of any complication in patients without complications at the time of enrolment, sRAGE was associated with the development of MACE over a 15-year follow-up in patients with type 2 diabetes who had no history of MACE at recruitment (OR for each SD-increase: 1.48, 95% CI 1.11–1.98; Additional file 1: Table S2).

Finally, we tested whether the AGEs/cRAGE ratio added significantly to the 10-year all-cause mortality risk predicted by the RECODe equation [51]. The term related to urinary albumin-to-creatinine ratio (UACR), which was not assessed at the time of recruitment, has been omitted from the equation, as recommended by the original publication. The 10-year probability of all-cause mortality in our cohort ranged from 1.9 to 76.9%, with a median of 13.6%. The category-free, continuous NRI of the predictive model obtained by adding the AGEs/cRAGE ratio to the 10-year all-cause mortality probability predicted by the RECODe equation was 0.090 (95% CI, 0.020–0.351) at 10 years of follow-up.

### Discussion

This study compared levels of soluble RAGE isoforms, AGEs, and their respective ratios in type 2 diabetes patients, with an average disease duration of 12.5 years, and age- and sex-matched healthy individuals, and explored their ability to predict all-cause mortality and development of MACE in patients with type 2 diabetes. Our results showed that circulating AGEs and sRAGE levels are increased in type 2 diabetes and that the increase of sRAGE is due to cRAGE increment since esRAGE did not change. Accordingly, the AGEs/sRAGE and AGEs/esRAGE ratios were also increased in type 2 diabetes. Moreover, we demonstrated that the AGEs/cRAGE ratio was able to predict all-cause mortality and that sRAGE was associated with the development of MACE in patients with type 2 diabetes. Finally, we built and internally validated a nomogram for the prediction of long-term survival probability in type 2 diabetes based on age, sex, HbA1c, SBP, and the AGE/cRAGE ratio.

Although several studies reported a significant increase in AGE levels in patients with type 2 diabetes [43, 52, 53], more conflicting evidence are available on sRAGE. Most cross-sectional studies focused on total sRAGE levels, with findings variable on type of diabetes, disease duration and presence of complications [54–57]. A smaller
A recent meta-analysis showed that circulating esRAGE was lower and inversely correlated with carotid intima-media thickness (IMT) in type 2 diabetes whereas a contrasting relationship was described between sRAGE and carotid IMT in patients with type 1 diabetes [58]. Overall, there is consensus that sRAGE levels reflect the extent of RAGE overexpression observed in immune [59], endothelial [60] and vascular smooth cells [61] in patients and animal models of diabetes. Our data support the evidence that the induction of FL-RAGE expression and its constitutive shedding by ADAM10 is responsible for the increment of circulating cRAGE in type 2 diabetes, however a concomitant increase of ADAM10 expression and activity, already observed in type 1 diabetes, cannot be excluded [62].

| Variable                        | Overall (n=542) | CTR (n=125) | T2DM (n=362) |
|---------------------------------|----------------|-------------|--------------|
| ADMA, SDMA, L-arginine, Telomere length, Total protein, PAI-1, hs-CRP, ApoB, ApoA1, HDL-C, Ferritin, Transferrin, Monocyte #, Monocyte %, Hematocrit, Hemoglobin, ALT, AST, Uric acid, eGFR, HOMA-index, Fasting insulin, HbA1c, Glucose, Waist/hip ratio, BMI, Weigh, Age, Disease duration, AGE/cRAGE, AGE/esRAGE, AGE/sRAGE, cRAGE, esRAGE, sRAGE, AGEs | | | |

**Fig. 3** Correlation plots showing the correlations among the different variables and AGEs, sRAGE isoforms and the derived ratios in the whole population and in CTR and type 2 diabetes (T2DM) subjects separately. The intensity of the color depends on the magnitude of the Spearman's correlation. Non-significant correlations (p ≥ 0.05) are crossed.
Here, we reported multiple associations between the presence of diabetic complications and AGEs, sRAGE isoforms and their ratios. In agreement with a previous study reporting an association between esRAGE and the severity of coronary artery disease in patients with type 2 diabetes [63], we observed a lower AGEs/esRAGE ratio in patients with a history of MACE. The strongest patterns of correlation were, however, observed for diabetic neuropathy and retinopathy. Indeed, the former was accompanied by lower levels of sRAGE (and higher AGEs/sRAGE ratio), while lower AGEs and increased cRAGE levels were observed in the latter. The interpretation of these apparently contrasting observations could be limited by the presence of a number of undiagnosed microvascular complications and might be related to the high degree of heterogeneity in terms of disease duration among patients with different complications. Indeed, it has been hypothesized that the shape of the relationship between AGEs and sRAGE isoforms is modelled according to the severity of type 2 diabetes complications, reflecting the progressive exhaustion of the sRAGE compensatory mechanism against AGEs [64].

Interestingly, we observed that AGEs/sRAGE, AGEs/cRAGE and AGEs levels were significantly lower in patients treated with insulin independent from HbA1c. Our findings are consistent with the in vitro observation that insulin not only increases both FL-RAGE and esRAGE expression but can also stimulate the shedding of cRAGE from the membrane-bound receptor [65].

Recently, we explored the role of circulating sRAGE isoforms in healthy human aging. When we previously determined serum concentration of both isoforms of sRAGE, esRAGE and cRAGE, and their ligands AGEs, HMGB1 and S100A8/A9 in a healthy population ranging from 20 to 90 years, we observed that cRAGE showed a negative correlation with age while RAGE ligands – AGEs and S100A8/A9 – increased with advancing age [32]. This result was confirmed in a recent study including LLIs, i.e., subjects older than 90 years [31]. Overall, LLIs are characterized by a lower AGEs/sRAGE ratio, due to esRAGE increase and AGEs reduction which may explain their reduced cardiovascular and metabolic risk [31]. Hence, we can assume that circulating cRAGE could be considered a reliable marker of chronological age, while esRAGE a protective factor associated with longevity.

The prognostic value of measuring sRAGE levels in blood is a matter of debate. Findings from the ADVANCE [43] and CARD [38] studies demonstrated that increased levels of sRAGE in patients with type 2 diabetes are

| Variable | Neurpathy | Nephropathy | Retinopathy | PAD | MACE |
|----------|-----------|-------------|-------------|-----|------|
| sRAGE    | −130.7    | 2.130       | 44.7        | 26.4| −9.875|
| cRAGE    | −30.40    | 28.49       | −5.965      | 0.016| 0.023|
| AGEs     | 3.187     | 0.158       | −0.487      | 0.001| 0.002|
| AGEs/sRAGE | 0.010   | 0.008       | 0.001       | 0.009| 0.005|
| AGEs/esRAGE | 0.020  | 0.038       | −0.001      | 0.005| 0.007|
| AGEs/cRAGE | 0.016   | 0.090       | 0.005       | 0.024| 0.006|

**Table 4** Age- and HbA1c-adjusted multiple quantile regression model for the evaluation of AGEs and sRAGE isoforms in type 2 diabetes complications

| Variable | Metformin | Sulphonylureas | Glinides | Insulin |
|----------|-----------|----------------|----------|---------|
| AGEs     | −1.462    | −2.088         | 0.992    | −5.060  |
| AGEs/sRAGE | 0.002  | −0.002         | 0.014    | −0.008  |
| AGEs/cRAGE | 0.002   | −0.003         | 0.034    | −0.026  |

**Table 5** Age- and HbA1c-adjusted multiple quantile regression model for the evaluation of AGEs and sRAGE isoforms according to type 2 diabetes treatments
independent predictors of new-onset or worsening renal disease, incident coronary heart disease and all-cause mortality within 5 years, without providing additional information on the specific isoforms. Here, we show for the first time that a predictive model encompassing age, sex, HbA1c, SBP, and the AGES/cRAGE ratio was able to stratify patients with type 2 diabetes according to the all-cause mortality risk. The model performed better for > 5 y follow-up time span, reaching its maximum predictive value at 10 years. Our results further corroborate the

### Table 6

Univariate and multivariate Cox regression analysis for the prediction of 15-year all-cause mortality in patients with type 2 diabetes

| Model | Univariate | Multivariate | Combined model |
|-------|------------|--------------|----------------|
| Predictor | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p |
| **Established risk factors** | | | | | | |
| Sex (male) | 1.20 (0.83–1.74) | 0.329 | – | – | 1.47 (0.94–2.30) | 0.093 |
| Age (years) | 1.11 (1.08–1.14) | < 0.001 | – | – | 1.10 (1.07–1.14) | < 0.001 |
| Disease duration (years) | 1.03 (1.01–1.04) | < 0.001 | – | – | 1.02 (1.01–1.04) | 0.008 |
| BMI (Kg/m²) | 1.01 (0.97–1.05) | 0.593 | – | – | 1.01 (0.96–1.06) | 0.647 |
| SBP (10 mmHg increase) | 1.48 (1.24–1.77) | < 0.001 | – | – | 1.37 (1.12–1.68) | 0.002 |
| HbA1c (%) | 1.09 (0.95–1.24) | 0.217 | – | – | 1.10 (0.93–1.30) | 0.255 |
| Total cholesterol (SD-increase) | 0.95 (0.79–1.14) | 0.552 | – | – | 1.21 (0.74–1.96) | 0.445 |
| LDL-C (SD-increase) | 0.82 (0.68–0.99) | 0.034 | – | – | 0.75 (0.50–1.14) | 0.179 |
| HDL-C (SD-increase) | 0.92 (0.75–1.13) | 0.427 | – | – | 0.88 (0.65–1.20) | 0.433 |
| Triglycerides (SD-increase) | 1.37 (1.10–1.71) | 0.005 | – | – | 1.15 (0.76–1.75) | 0.514 |
| eGFR (10 mL/min increase) | 0.78 (0.72–0.86) | < 0.001 | – | – | 0.94 (0.86–1.03) | 0.192 |
| hs-CRP (SD-increase) | 1.14 (1.00–1.31) | 0.052 | – | – | 1.18 (1.01–1.39) | 0.036 |
| **Relevant treatments** | | | | | | |
| Insulin | 1.66 (1.08–2.54) | 0.020 | – | – | 0.89 (0.51–1.55) | 0.675 |
| Metformin | 0.68 (0.46–1.01) | 0.058 | – | – | **0.63 (0.41–0.97)** | **0.037** |
| Sulphonylureas | 1.10 (0.76–1.58) | 0.624 | – | – | 0.81 (0.53–1.23) | 0.324 |
| Statins | 1.18 (0.75–1.87) | 0.468 | – | – | 0.93 (0.56–1.56) | 0.785 |
| Vitamin K antagonists | 1.57 (0.94–2.62) | 0.088 | – | – | 1.29 (0.74–2.26) | 0.376 |
| **Candidate predictors (SD-increment)** | | | | | | |
| sRAGE | 0.89 (0.74–1.07) | 0.225 | – | – | – | – |
| esRAGE | 0.93 (0.77–1.13) | 0.469 | – | – | – | – |
| cRAGE | 0.93 (0.77–1.12) | 0.436 | – | – | – | – |
| AGES | 0.88 (0.70–1.01) | 0.249 | – | – | – | – |
| AGES/sRAGE | 0.90 (0.73–1.11) | 0.326 | 0.86 (0.69–1.08) | 0.203 | 0.79 (0.61–1.02) | 0.072 |
| AGES/esRAGE | 0.97 (0.77–1.21) | 0.760 | 0.84 (0.66–1.07) | 0.159 | 0.80 (0.71–1.11) | 0.289 |
| AGES/cRAGE | 1.20 (1.06–1.35) | 0.005 | **1.24 (1.07–1.43)** | **0.004** | 1.30 (1.15–1.47) | < 0.001 |
| cRAGE/esRAGE | 0.95 (0.78–1.16) | 0.629 | 0.84 (0.69–1.02) | 0.080 | – | – |

In the multivariate model, each ratio is adjusted for established risk factors and relevant treatments. Combined model adjusted for AGES/sRAGE, AGES/esRAGE, AGES/cRAGE, established risk factors and relevant treatments. Significant predictors at the multivariate analysis are displayed in **bold**.
Fig. 4 (See legend on previous page.)
significant of the assessment of AGEs and their circulating receptors in type 2 diabetes and provide added value for a more comprehensive evaluation of sRAGE isoforms, also in relation to AGE levels. In this regard, it has been demonstrated that sRAGE acts as a decoy receptor by preventing ligands from interacting with membrane-bound FL-RAGE [66]. While no agreement has been reached on the sRAGE isoform concentrations required to scavenge circulating ligands [39], here we provide clues that a disproportionate presence of AGEs not adequately counterbalanced by the cRAGE isoform is associated with reduced survival in type 2 diabetes. Our results uncovered a complex pattern of association between circulating sRAGE isoforms and AGEs in determining the risk of mortality, which supports the growing consensus that the ratios between AGEs and sRAGE isoforms may be more informative for the clinical course rather than sRAGE alone. Notably, the AGEs/cRAGE ratio led to a significant, albeit modest, improvement in the ability of the already established RECODe model of predicting 10-year all-cause mortality in type 2 diabetes based on age, sex, ethnicity, smoking, SBP, history of MACE, HbA1c, total cholesterol, HDL-C, serum creatinine, and UACR [51]. Furthermore, we observed that each SD-increase in plasma sRAGE was independently associated with the development of MACE during a >15-years follow-up in type 2 diabetes patients with no history of MACE at recruitment. Our findings are consistent with previous reports showing that serum sRAGE levels were independently associated with CV outcomes in type 2 [38, 44] and type 1 diabetes [41].

A number of limitations should be acknowledged. First, reliance on a single baseline measurement for AGEs and sRAGE isoforms could have introduced an additional bias due to biological and analytical variability. Second, due to the unavailability of data regarding the mortality of control subjects we were unable to estimate the excess mortality in diabetes due to the increase of circulating AGEs and sRAGE. Third, the lack of data on the UACR at the time of recruitment prevented us to calculate the full-term RECODe equation for the 10-year all-cause mortality. However, we believe that our results were minimally affected by this shortcoming, given the relatively small impact of UACR on the equation results (β = 0.00039) and the proven robustness of the equation in presence of missing data. Moreover, external validation of the nomogram was not performed due to the relatively small sample size, thus limiting the generalization of our findings. Finally, the high heterogeneity of diabetes phenotypes in our cohort prevented us to draw definitive conclusions on the modulation of these biomarkers according to specific complications and treatments but allowed us to perform a more comprehensive and accurate analysis of their prognostic role in type 2 diabetes.

Conclusions

In conclusion, our data support the assessment of circulating AGEs and soluble RAGE isoforms in patients with type 2 diabetes as predictors of MACE and all-cause mortality. Further multicenter external validation studies should be performed to verify the prognostic value and generalizability of our nomogram.

Abbreviations

ADA: American Diabetes Association; AGEs: Advanced glycation end-products; ApoA1: Apolipoprotein A1; ARDs: Age-related diseases; AUC: Area Under the Curve; BMI: Body mass index; CHD: Coronary artery disease; CI: Confidence interval; cRAGE: Cleaved RAGE; CTR: Control subjects; CV: Cardiovascular; CVD: Cardiovascular disease; DAMPS: Damage-associated molecular patterns; DBP: Diastolic blood pressure; eNOS: Endothelial nitric oxide synthase; esRAGE: Endogenous secretory; FL-RAGE: Membrane-bound RAGE; HbA1c: Hemoglobin A1c; HDL-C: HDL cholesterol; HOMA: Homeostatic model assessment; HR: Hazard ratio; hs-CRP: High sensitivity C Reactive Protein; IMT: Intima-media thickness; IQR: Interquartile range; LDL-C: LDL cholesterol; LLIs: Long living individuals; MACE: Major adverse cardiac events; OGTT: Oral glucose tolerance test; PAI-1: Plasminogen activator inhibitor-1; PAMPs: Pathogen-associated molecular pattern; RAGE: Receptor for advanced glycation end-products; ROS: Reactive oxygen species; SBP: Systolic blood pressure; sRAGE: Soluble RAGE; T2DM-C: Type 2 diabetes with complications; T2DM-NC: Type 2 diabetes without complications; UACR: Urinary albumin-to-creatinine ratio; WHR: Waist-hip ratio.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01535-3.

Acknowledgements

We thank F. Scavello for technical help (Centro Cardiologico Monzino-IRCCS).

Author contributions

DR, ET, and ARB performed the clinical study and routine laboratory analyses. SC and FM performed ELISA assay. JS and AG analysed the data and prepared figures. AR, FO, and ARB supervised the project. JS, AG, AR and FO wrote the manuscript. MCV reviewed the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by funding from the Italian Ministry of Health (Ricerca Corrente to Centro Cardiologico Monzino-IRCCS and IRCCS INRCA) and Università Politecnica delle Marche (RSA Grant to FO). FM was supported by Fondazione IEO-CCM Fellowship 2020.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of IRCCS INRCA hospital (approval no. 34/CdB/03) and conducted in accordance with the principles contained within the Declaration of Helsinki. All patients enrolled in the study provided written informed consent.

Consent for publication
Not applicable.

Competing interests
All authors declare no competing interests associated with this manuscript. The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Author details
1 Laboratory Medicine Unit, Azienda Ospedaliero Universitaria “Ospedali Riuniti”, Ancona, Italy. 2 Laboratory Medicine Unit, Centro Cardiologico Monzino-IRCCS, Milan, Italy. 3 Experimental Cardio-Oncology and Cardiovascular Aging Unit, Centro Cardiologico Monzino-IRCCS, Milan, Italy. 4 Clinical Laboratory and Molecular Diagnostic, IRCCS INRCA, Ancona, Italy. 5 Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Milan, Italy. 6 Metabolic Diseases and Diabetology Department, IRCCS INRCA, Ancona, Italy. 7 Scientific Direction, IRCCS INRCA, Ancona, Italy.

Received: 28 April 2022  Accepted: 26 May 2022
Published online: 06 June 2022

References
1. Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–29.
2. Simm A, Muller B, Nass N, Hofmann B, Bushnaq H, Silber RE, et al. Protein glycation—between tissue aging and protection. Exp Gerontol. 2015;68:71–5.
3. Wauteir MP, Chapprey O, Corda S, Stern DM, Schmidt AM, Wauteir JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280(5):E685-94.
4. Ruiz HH, Ramasamy R, Schmidt AM. Advanced glycation end products: building on the concept of the “common soil” in metabolic disease. Endocrinology. 2020;161(1):bgz006.
5. Kunimoto M, Yokoyama M, Shimada K, Matsubara T, Ouchi N, et al. Relationship between skin autofluorescence and early events in patients with heart failure undergoing cardiac rehabilitation. Cardiovasc Diabetol. 2021;20(1):208.
6. Yoazati K, Lefrandt JD, Noordzij MJ, Oomen PHN, Brouwer T, Jager J, et al. Accumulation of advanced glycation end products is associated with macrovascular events and glycolytic control with microvascular complications in type 2 diabetes mellitus. Diabet Med. 2018;35:1242.
7. Chen Q, Huang Q, Liu W, Zhou X. Advanced glycation end products via skin autofluorescence as a new biomarker for major adverse cardiovascular events: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2022;32(3):1083–92.
8. Birukov A, Cuadrat R, Polemiti E, Eichelmann F, Schulze MB. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and non-glycemic individuals: a cross-sectional study. Cardiovasc Diabetol. 2021;20(1):110.
9. Fritz G, RAGE: a single receptor fits multiple ligands. Trends Biochem Sci. 2011;36(12):625–32.
10. Plantner D, Nallar S, Richard K, Spiegel D, Collins KD, Vogel SN. Classically activated macrophages produce methylglyoxal which induces a TLR4- and RAGE-independent proinflammatory response. J Leukoc Biol. 2021;109(3):605–19.
11. Sessa L, Gatti E, Zeni F, Antonelli A, Catucci A, Koch M, et al. The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS ONE. 2014;9(1):e86903.
12. Antonelli A, Di Maggio S, Rejman J, Sanvitto F, Rossi A, Catucci A, et al. The shedding-derived soluble receptor for advanced glycation end products sustains inflammation during acute Pseudomonas aeruginosa lung infection. Biochim Biophys Acta. 2017;1861(2):354–64.
13. Scavello F, Zeni F, Milano G, Macri F, Castiglione S, Zuccolo E, et al. Soluble receptor for advanced glycation end-products regulates age-associated cardiac fibrosis. Int J Biol Sci. 2021;17(10):2399–416.
14. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the prilam response to stress. J Leukoc Biol. 2007;82(2):204–12.
15. Mahajan N, Dhawan V. Receptor for advanced glycation end product effects (RAGE) in vascular and inflammatory diseases. Int J Cardiol. 2013;168(3):1788–94.
16. Song F, Hurdado del Pozo C, Rosario R, Zou YS, Ananthakrishnan R, Xu X, et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes. 2014;63(6):1948–65.
17. Egana-Gorrondo L, Lopez-Diez R, Yepuri G, Ramirez LS, Reverdatto S, Gugger PF; et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models. Front Cardiovasc Med. 2020;7:57.
18. Manigrasso MB, Pan J, Rai V, Zhang J, Reverdatto S, Quadri N, et al. Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction. Sci Rep. 2016;6:22450.
19. Raucci A, Cugusi S, Antonelli A, Barabino SW, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22(10):3716–27.
20. Tsoporis JN, Hatzigelaki E, Gupta S, Izhar S, Salpeas V, Tsiavou A, et al. Circulating ligands of the receptor for advanced glycation end products and the soluble form of the receptor modulate cardiovascular cell apoptosis in diabetes. Molecules. 2020;25(22):5235.
21. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr., Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4(9):1025–31.
22. Sourris KC, Morley AL, Kotika A, Samuel P, Coughlan MT, Penfold SA, et al. Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia. 2010;53(11):2442–51.
23. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, et al. Receptor for AGE (RAGE) mediates neoimal formation in response to arterial injury. Circulation. 2003;107(17):2238–43.
24. Momma H, Niu K, Kobayashi Y, Huang C, Chuo M, Otoro A, et al. Lower serum endogenous secretory receptor for advanced glycation end product levels as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study. J Clin Endocrinol Metab. 2014;99(2):587–93.
25. Liu Q, Chen HB, Luo M, Zheng H. Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertensive patients. Genet Mol Res. 2016;15(2):15.
26. Dzioe E, Briganti S, Delvene A, Vanello E, Ermetici F, Secchi F, et al. Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women. Eur J Nutr. 2017;56(8):2557–64.
27. Di Pino A, Urbano F, Scialli R, Di Mauro S, Filippello A, Scamporinno A, et al. 1h postload glycaemia is associated with low endogenous secretory receptor for advanced glycation end product levels and early markers of cardiovascular disease. Cells. 2019;8(8):910.
28. Di Pino A, Urbano F, Zagami RM, Filippello A, Di Mauro S, Piro S, et al. Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes. J Clin Endocrinol Metab. 2016;101(4):1701–9.
29. Miranda ER, Somal VS, Mey JT, Blackburn BK, Wang E, Faraba S, et al. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313(6):E631-E40.
30. Prakash J, Pichchadze G, Trofinov S, Livshits G. Age and genetic deter-
iminants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population. Mech Ageing Dev. 2015;145:18–25.

31. Scavullo F, Tedesco CC, Castriglione S, Maciag A, Sangalli E, Veglia F, et al. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals. Biomark Med. 2021;15(1):785–96.

32. Scavullo F, Zeni F, Tedesco CC, Mensa E, Veglia F, Procopio AD, et al. Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging. Aging (Albany NY). 2019;11(6):1648–63.

33. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudieux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem. 2005;51(9):1749–50.

34. Nakamura K, Yamagishi S, Adachi H, Kunpra-Nakamura Y, Mattis T, Yoshida T, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med. 2007;13(3–4):185–9.

35. Gomez-Cabero D, Walter S, Abbugessaia I, Milamas-Herraiz R, Palomares LB, Butcher L, et al. A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European countries. Geroscience. 2021;43:1317–29.

36. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis. 2009;53(1):51–8.

37. Butcher L, Carnicero JA, Gomez-Cabero D, Artigues JF, Peres K, Garcia-Garcia FJ, et al. Increased levels of soluble receptor for advanced glycation end-products (RAGE) are associated with a higher risk of mortality in frail older adults. Age Ageing. 2019;48(5):696–702.

38. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone JM, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDIS trial. Diabetes. 2011;60(9):2379–85.

39. Erusalimsky JD. The use of the soluble receptor for advanced glycation end-products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol. 2021;2:101958.

40. Reichert S, Tiebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A, et al. Soluble form of receptor for advanced glycation end products and incidence of cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9.

41. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010;59(8):2597–32.

42. Thomas MC, Soderlund J, Lehto M, Makinen VP, Moran JL, Cooper ME, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia. 2011;54(10):2669–77.

43. Thomas MC, Woodward M, Neal B, Li Q, Pickering R, Marre M, et al. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. Diabetes Care. 2015;38(10):1891–7.

44. Fujisawa K, Katakami N, Kaneto H, Naka T, Takahara M, Sakamoto F, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227(2):429–35.

45. Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti M, Georgoulis M, et al. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;85:120–7.

46. Prasad K, Dhar I, Zhou Q, Elmohsi H, Shoker M, Shoker A. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem. 2016;423(1–2):105–14.

47. Testa R, Vanhooren V, Bonfigli AR, Boemi M, Oliveri F, Ceirello A, et al. N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS ONE. 2015;10(3):e0119983.

48. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30:652.

49. Xiao N, Xu QS, Li MZ. Building Nomograms for Penalized Cox Models with High-Dimensional Survival Data. BioRxiv. 2016. https://doi.org/10.1101/065524.

50. Pencina MJ, D’Agostino RB, Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(11):1–21.

51. Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of net equations for complications of type 2 diabetes (RECODE) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5(10):788–98.

52. El-Mesallamy HO, Hamdy NM, Ezzat OA, Reda AM. Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med. 2011;59(8):1233–8.

53. Adeshara KA, Bangar N, Diwan AG, Tupe RS. Plasma glycation adducts and various RAGE isoforms are intricately associated with oxidative stress and inflammatory markers in type 2 diabetes patients with vascular complications. Diabetes Metab Syndr. 2022;16(3):102441.

54. Farhan SS, Hussain SA. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(4):2457–61.

55. Humpert PM, Djunic Z, Kopf S, Rudofsky G, Morcos M, Navroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007;6:9.

56. Skrha J, Jr, Kalousova M, Svarcova J, Muraviska A, Kvasnicka J, Landova L, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120(5):277–81.

57. Reyaz A, Alam S, Chandra K, Kohli S, Agarwal S. Methylglyoxal and soluble RAGE in type 2 diabetes mellitus: association with oxidative stress. J Diabetes Metab Disord. 2020;19(1):513–21.

58. Wang X, Wang Q, Wei D, Chang X. Association between soluble recep-
tor for advanced glycation end product and endogenous secretory soluble receptor for advanced glycation end product end products and carotid atherosclerosis in diabetes: a systematic review and meta-analysis. Can J Diabetes. 2021;45(7):634–40.

59. Phimphila M, Pothacharoen P, Klongtauvel P. Age-influenced receptors of advanced glycation end product overexpression associated with osteogenic differentiation impairment in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2021;12:726182.

60. Jeong J, Lee J, Lim J, Cho A, S, Ahn S, Lee M, et al. Soluble RAGE attenu-
es angii-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE. Exp Mol Med. 2019;51(9):1–15.

61. Simard E, Solladit T, Maltais JS, Boucher J, D’Oleane-Juste P, Grandbois M. Receptor for advanced glycation end-products signaling interferes with the vascular smooth muscle cell contractile phenotype and function. PLoS ONE. 2015;10(8):e0128881.

62. Lee AC, Lam JK, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Serum level of soluble receptor for advanced glycation end products is associated with a disintegrin and metalloproteinase 10 in type 1 diabetes. PLoS ONE. 2015;10(9):e0137330.

63. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis. 2009;206(2):540–5.

64. Aubert CE, Michel PL, Gillyer P, Jaisson S, Fonfrede M, Morel F, et al. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014;30(8):679–85.

65. Lam JK, Wang Y, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med. 2013;30(6):702–9.
66. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009;52(11):2251–63.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.